Codexis

Отрасль

Промышленная химия

Темы

Ферменты и биокатализ

Роль

Производитель — “…proteins for pharmaceutical manufacturing and diagnostic applications. Founded in 2002, the company utilizes i…”

Почему это биоэкономика

Codexis конструирует ферменты для фармацевтического биокатализа и производства РНК.

Пока не указана поставщиком в решениях с доказательствами.

Последние новости 5

Найдены автоматическим поиском; краткие пересказы написаны машиной на английском. В заголовке есть название компании, или пересказ о ней — перед использованием сверяйтесь с источником.

• 2026-09-28 Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA :: … ir.codexis.com
  Codexis announces a collaboration with a leading siRNA drug innovator to use its ECO Synthesis platform for enzymatic, stereo-defined fragment synthesis and ligation into final siRNA duplexes, comparing with solid-phase methods to assess purity and quality. This underscores …
• 2026-08-12 Codexis Reports Second Quarter 2026 Financial Results - BioSpace biospace.com
  Codexis reported Q2 2026 revenue of $14.9 million, reiterated full-year guidance (revenues $72–$76 million; gross margin high‑60s%), and healthy cash runway (pro forma ~$80 million after a July $25 million equity raise). The company highlighted progress commercialization of its …
• 2026-08-03 Codexis Appoints David Butler, PhD, to Strategic Advisory globenewswire.com
  Codexis is expanding its strategic leadership by adding David Butler, PhD, to its Strategic Advisory Board, signaling a focus on advancing siRNA therapeutics and industrializing its enzymatic technology for scalable manufacturing. The company also acknowledges Carole Cobb’s …
• 2026-08-03 Codexis Appoints David Butler, PhD, to Strategic Advisory globenewswire.com
  Codexis is expanding its strategic leadership by adding David Butler, PhD, to its Strategic Advisory Board to bolster its growth and expertise in siRNA therapeutics and scalable enzymatic manufacturing, while thanking Carole Cobb for her contributions as she steps down. The …
• 2026-07-24 Codexis Prices $23.1M Public Offering | GenomeWeb genomeweb.com
  Codexis is raising about $23.1 million from a public stock offering at $1.50 per share (approximately 16.7 million shares with an option for up to 2.5 million more), to fund working capital, R&D, and general corporate purposes; the company also reports solid Q1 revenue growth …

Похожие компании

Genencor · Amyris · EDT-Enzymatic Deinking Technologies, LLC · Jeneil Biotech, Inc. · Dyadic Applied BioSolutions · Yzymes · Protein Evolution · Mascoma LLC

Регистрационные номера

• I.R.S. Employer Identification No.: 71-0872999

Финансирование

• Последний раунд: Post ipo equity · 2026-07-01
• Привлечено всего: US$ 229,3 M

Из автоматизированного исследования (сайты компаний, отчётность, коммерческий справочник компаний); вручную не проверено. Регистрационные номера сверяйте в официальном реестре.